Home › Research › How common it is
Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study
van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM.. The Lancet. Neurology, 2006-08-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Amyloid beta peptides (Abeta) are important components of plaques in Alzheimer's disease. Plasma concentrations of Abeta(1-40) and Abeta(1-42) rise with age and are increased in people with mutations that cause early-onset Alzheimer's disease. However, Abeta(1-42) concentrations may decrease early in the dementia process. We postulated that concentrations of Abeta(1-40) and Abeta(1-42) in plasma are associated with risk of dementia. Methods We did a case-cohort study embedded in the prospective, population-based Rotterdam Study. Of 6713 participants at risk for dementia, a random sample of 1756 people was drawn. During follow-up (mean 8.6 years), 392 incident dementia cases were identified. We investigated the association between plasma Abeta concentrations and risk of dementia and its subtypes using Cox proportional hazard models. Findings High concentrations of Abeta(1-40) but not Abeta(1-42) at baseline were associated with an increased risk of dementia. Compared with the first quartile of Abeta(1-40), age and sex-adjusted hazard ratios for dementia for the second, third, and fourth quartiles were 1.07 (95% CI 0.72-1.58), 1.16 (0.78-1.70), and 1.46 (1.01-2.12). People with an increased Abeta(1-42)/Abeta(1-40) ratio had a reduced risk of dementia. Compared with the first quartile of the Abeta(1-42)/Abeta(1-40) ratio, hazard ratios for the second, third, and fourth quartiles were 0.74 (0.53-1.02), 0.62 (0.44-0.88), and 0.47 (0.33-0.67). Associations were similar for Alzheimer's disease and vascular dementia. Interpretation High plasma concentrations of Abeta(1-40), especially when combined with low concentrations of Abeta(1-42), indicate an increased risk of dementia. A potential role of plasma Abeta concentrations as a marker of incipient dementia warrants further investigation.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 6,713 participants. This cohort study found that high plasma Abeta(1-40) concentrations were associated with increased dementia risk, while a higher Abeta(1-42)/Abeta(1-40) ratio was associated with reduced risk. It identifies a possible blood marker of risk but does not test any treatment, cure, or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
van Oijen, M., Hofman, A., Soares, H. D., Koudstaal, P. J., & Breteler, M. M. (2006). Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(06)70501-4
Vancouver
van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. The Lancet. Neurology. 2006. doi:10.1016/s1474-4422(06)70501-4. PMID: 16857570.
BibTeX
@article{vanoijen2006-16857570,
author = {van Oijen, M. and Hofman, A. and Soares, H. D. and Koudstaal, P. J. and Breteler, M. M.},
title = {{Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study}},
journal = {The Lancet. Neurology},
year = {2006},
doi = {10.1016/s1474-4422(06)70501-4},
pmid = {16857570},
url = {https://doi.org/10.1016/s1474-4422(06)70501-4}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- We postulated that concentrations of Abeta(1-40) and Abeta(1-42) in plasma are associated with risk of dementia.
- Findings High concentrations of Abeta(1-40) but not Abeta(1-42) at baseline were associated with an increased risk of dementia.
- Compared with the first quartile of Abeta(1-40), age and sex-adjusted hazard ratios for dementia for the second, third, and fourth quartiles were 1.07 (95% CI 0.72-1.58), 1.16 (0.78-1.70), and 1.46 (1.01-2.12).
- Compared with the first quartile of the Abeta(1-42)/Abeta(1-40) ratio, hazard ratios for the second, third, and fourth quartiles were 0.74 (0.53-1.02), 0.62 (0.44-0.88), and 0.47 (0.33-0.67).
- Interpretation High plasma concentrations of Abeta(1-40), especially when combined with low concentrations of Abeta(1-42), indicate an increased risk of dementia.
Why it matters
This cohort study found that high plasma Abeta(1-40) concentrations were associated with increased dementia risk, while a higher Abeta(1-42)/Abeta(1-40) ratio was associated with reduced risk. It identifies a possible blood marker of risk but does not test any treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Alzheimer's in numbers →
Study details
- Study designcohort study
- Participants6,713
- Evidence strengthModerate
How this study scored 67/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (The Lancet. Neurology) |
| Journal's citation record | 3 / 4 | The Lancet Neurology: journal h-index 457 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2006 — older than 20 years, still counted |
| Sample size | 3 / 4 | 6,713 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 459 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 20.9 citations a year over 22 year(s) since 2006 |
| Impact for its field and year | 5 / 6 | Cited 21.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 29 other studies in this library |
| Still being cited | 2 / 4 | Cited 35 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Monique M.B. Breteler: h-index 162 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Erasmus MC: institution h-index 1,321 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 16857570) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 67 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
29 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in How common it is from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.